Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10634
Title: Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis.
Authors: Commons, R J
Grivas, R
Currie, B J
Affiliation: Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia..
Issue Date: Dec-2014
Citation: Internal medicine journal 2014-12; 44(12a): 1245-6
Abstract: Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10634
DOI: 10.1111/imj.12610
Type: Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Subjects: Burkholderia pseudomallei
immunosuppression
melioidosis
monoclonal antibody
psoriatic arthritis
Adalimumab
Amoxicillin-Potassium Clavulanate Combination
Anti-Infective Agents
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Arthritis, Psoriatic
Burkholderia pseudomallei
Humans
Male
Melioidosis
Middle Aged
Risk Factors
Treatment Outcome
Trimethoprim, Sulfamethoxazole Drug Combination
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.